FDA Approved Products

6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
CORDRAN
flurandrenolide
LOE Approaching
Almirall
TOPICAL · TAPE
1969
NDA
30/100
CORDRAN
flurandrenolide
LOE Approaching
TOPICAL · OINTMENT
1965
NDA
30/100
CORDRAN SP
flurandrenolide
LOE Approaching
TOPICAL · CREAM
1965
NDA
30/100
COREG
carvedilol
LOE Approaching
Viatris (2)
ORAL · TABLET
mild-to-severe chronic heart failure of ischemiccardiomyopathic origin+11
1995
NDA
30/100
CORGARD
nadolol
LOE Approaching
ORAL · TABLET
hypertensionto lower blood pressure+1
1979
SMNDA
30/100
CORLOPAM
fenoldopam mesylate
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1997
NDA
30/100
CORPHEDRA
ephedrine sulfate
Peak
Pfizer
INTRAVENOUS · SOLUTION
clinically important hypotension occurring in the setting of anesthesia
2017
NDA
30/100
CORSYM
chlorpheniramine polistirex; phenylpropanolamine polistirex
LOE Approaching
UCB Pharma
ORAL · SUSPENSION, EXTENDED RELEASE
1984
NDA
30/100
CORTEF
hydrocortisone cypionate
LOE Approaching
Pfizer
ORAL · SUSPENSION
dermatomyositistemporal arteritis+15
1955
NDA
30/100
CORTEF
hydrocortisone
LOE Approaching
Pfizer
ORAL · TABLET
the following conditionsRheumatoid arthritis+7
1952
NDA
30/100
CORTEF ACETATE
hydrocortisone acetate
LOE Approaching
Pfizer
TOPICAL · OINTMENT
1953
NDA
30/100
CORTENEMA
hydrocortisone
LOE Approaching
ANI Pharmaceuticals
RECTAL · ENEMA
ulcerative colitis
1966
NDA
30/100
CORTICOTROPIN
corticotropin
LOE Approaching
INJECTION · INJECTABLE
the following disorders: 1Rheumatoid arthritis+3
1957
NDA
30/100
CORTIFOAM
hydrocortisone acetate
LOE Approaching
Viatris (2)
RECTAL · AEROSOL, METERED
1982
NDA
30/100
CORTISONE ACETATE
cortisone acetate
LOE Approaching
ORAL · TABLET
stressfatigue+1
2001
NDA
30/100
CORTISONE ACETATE
cortisone acetate
LOE Approaching
Pfizer
ORAL · TABLET
stressfatigue+1
1951
NDA
30/100
CORTISONE ACETATE
cortisone acetate
LOE Approaching
ORAL · TABLET
stressfatigue+1
1952
NDA
30/100
CORTISPORIN
bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
R-Pharm US
OPHTHALMIC · OINTMENT
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1971
NDA
30/100
CORTISPORIN
bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
TOPICAL · OINTMENT
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1957
NDA
30/100
CORTISPORIN
hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
OPHTHALMIC · SUSPENSION/DROPS
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1964
NDA
30/100
CORTISPORIN
hydrocortisone; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
OTIC · SOLUTION/DROPS
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1975
NDA
30/100
CORTISPORIN
hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate
LOE Approaching
Monarch Therapeutics
TOPICAL · CREAM
superficial bacterial infections of the external auditory canalcaused by organisms susceptible to the action of the antibiotics
1963
NDA
30/100
CORTONE
cortisone acetate
LOE Approaching
Merck & Co.
ORAL · TABLET
stressfatigue+1
1950
NDA
30/100
CORTONE
cortisone acetate
LOE Approaching
Merck & Co.
INJECTION · INJECTABLE
stressfatigue+1
1950
NDA
30/100
← PreviousPage 41 of 277Next →